Opinion

Video

Novel Systemic and Topical Treatment for Plaque Psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis

1:06 Therapeutic innovations in psoriasis

6:55 Challenges with individualizing treatment

7:51 Selective mechanism of deucravacitinib (TYK2 inhibitor)

11:25 Clinical outcomes of deucravacitinib in psoriasis

15:38 Positioning deucravacitinib in the treatment algorithm

17:58 Deucravacitinib vs apremilast

21:41 Novel non-steroidal topicals- tapinarof and roflumilast

26:06 Efficacy and safety of novel topicals

32:13 Benefits of topicals with cross indications

33:55 Remittive effect of tapinarof

37:08 Summary of novel treatments in psoriasis

39:45 Personalizing psoriasis treatment

Related Videos
Implications of Findings on Patient-Reported Outcomes for Roflumilast Foam, with Melinda Gooderham, MD
New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.